Amendment 0001 CR.pdf

This document is an amendment to Solicitation HT9402-24-Q-9301 issued by the Defense Health Agency. The amendment updates the RFQ document number from HT9402-23-Q-9301 to HT9402-24-Q-9301, adds page numbers to the RFQ document, and removes two pharmaceutical agents, Endur-Amide and Endur-Thine, from the Antilipidemics-1: Non-Statin Agents and Combos class. The original solicitation is for the Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program. The solicitation includes four drug classes that will be reviewed by the P&T Committee in August 2024: Antilipidemics-1: Non-Statin Agents and Combos, Antilipidemics-1: Statins, Leukemia and Lymphoma Agents: Bruton Tyrosine Kinase Inhibitors, and Antipsychotic Agents: Parkinson's Psychosis. Responses to the clinical questions in Part 3.4 are due by the date stated in Part 2.4, and a pre-quote teleconference is scheduled for April 24, 2024.